Myriad myPath Melanoma Test Reduced Indeterminate Cases By 76% And Changed Treatment In 35 % Of Cases
September 09, 2014 at 07:08 AM EDT
Myriad Genetics, Inc. (Nasdaq: MYGN) today presented results from a pivotal clinical utility study of the Myriad myPath™ Melanoma test ...
